EUVIMEDEUVIMED entdecken
Crossref

L26/O-122 Managing embryos with segmental aneuploidy: key considerations for patient counseling

A. Besser

Human Reproduction · 01.07.2026 · 41 (Supplement_1)

DOI: 10.1093/humrep/deag083.122 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von A. Besser.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Preimplantation genetic testing for aneuploidy (PGT-A) is well-established for identifying whole chromosome aneuploidy (WCA), which is typically meiotic in origin and uniformly present throughout the embryo. The clinical implications of chromosomal mosaicism, which is inferred based on intermediate copy number between monosomy/trisomy and disomy, have also been increasingly characterized in recent years. In contrast, full copy number segmental aneuploidy (SegA), defined as subchromosomal gain or loss, remains considerably more challenging to interpret in clinical practice. Its biological origin, distribution within the embryo, and impact on reproductive outcomes are not fully understood, contributing to uncertainty in embryo selection and patient counseling. This presentation synthesizes current evidence from rebiopsy concordance studies, retrospective and prospective outcome data, and real-world clinical experience to evaluate the clinical significance of SegA detected by PGT-A. Available data suggest that SegA is associated with lower intra-embryonic concordance and reduced reproductive potential compared to WCA, suggesting that it may reflect either technical artifact or mosaicism arising from mitotic error. However, interpretation is complicated by variability in laboratory reporting thresholds, differences in testing platforms, and heterogeneity in bioinformatic pipelines, limiting generalizability across PGT-A laboratories. Despite overall lower success rates, healthy live births following transfer of embryos with SegA have been reported. There remains a possibility, however, that a detected SegA represents a true embryonic abnormality that could persist in the fetus and result in clinical consequences. This uncertainty underscores the importance of thorough pre-transfer counseling and shared decision-making. SegA represents a distinct and evolving category within PGT-A reporting that differs from euploid, whole chromosome aneuploid, and mosaic results. Counseling strategies may draw from established frameworks for mosaic embryo transfer but should emphasize the more limited evidence base for SegA. Patients should be counseled about the reduced chance of live birth, potential clinical risks, and the option for confirmatory prenatal testing in the setting of an ongoing pregnancy. Overall, the identification of SegA in embryo biopsies further challenges traditional binary classifications in PGT-A and highlights the need for nuanced, data-driven counseling and individualized clinical decision-making.

Zitieren

APA

Besser, A. (2026). L26/O-122 Managing embryos with segmental aneuploidy: key considerations for patient counseling. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.122

Vancouver

Besser A. L26/O-122 Managing embryos with segmental aneuploidy: key considerations for patient counseling. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.122

BibTeX
@article{Besser2026,
  author = {Besser, A.},
  title = {L26/O-122 Managing embryos with segmental aneuploidy: key considerations for patient counseling},
  journal = {Human Reproduction},
  year = {2026},
  volume = {41},
  number = {Supplement_1},
  doi = {10.1093/humrep/deag083.122}
}
Kostenlos starten →